Imatinib—A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015 | Hematology | JAMA Oncology | JAMA Network
[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 35.153.39.7. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
May 2015

Imatinib—A New Tyrosine Kinase Inhibitor for First-Line Treatment of Chronic Myeloid Leukemia in 2015

Author Affiliations
  • 1Department of Health Sciences, University of Milano-Bicocca, Monza, Italy
  • 2Section of Hematology, San Gerardo Hospital, Monza, Italy
JAMA Oncol. 2015;1(2):143-144. doi:10.1001/jamaoncol.2015.50

Imatinib mesylate changed the prognosis for chronic myeloid leukemia (CML) so dramatically that patients with newly diagnosed CML starting treatment with imatinib now have a normal life expectancy,1,2 compared with the historical median survival of 2 to 3 years. In addition to its outstanding therapeutic activity, imatinib possesses a remarkably safe profile.

Second- and third-generation tyrosine kinase inhibitors (TKIs) were developed primarily for second- and third-line use: bosutinib monohydrate, dasatinib, nilotinib, and ponatinib hydrochloride constitute a set of formidable “spare wheels” for patients whose imatinib treatment fails, giving a viable option to more than 50% of them. These drugs contributed to achieving the observed normal life expectancy in patients with CML who start first-line imatinib treatment. Dasatinib and nilotinib also obtained first-line indication and have been aggressively marketed as a replacement for the “aging” imatinib.

×